Rationale: The study aims to explore the degradation products of gimeracil via forced degradation analysis, necessitating the development of an analytical method for liquid chromatography-mass spectrometry (LC-MS). Methods: Gimeracil was subjected to various stress conditions in accordance with International Conference on Harmonization guidelines, including acidic, alkaline, oxidative, photolytic, and thermal conditions. The analytical method was optimized to effectively separate gimeracil from its potential degradation products. Results: Under acidic, alkaline, photolytic, and thermal conditions, minimal degradation of gimeracil was observed. However, oxidative stress led to significant degradation, resulting in the identification of fourteen previously unreported degradation products. Structural elucidation of these products was achieved through orbitrap HRMS (high-resolution mass spectrometry) and HRMS/MS spectra analysis, with pathways for the formation of various daughter ions provided for some degradation products. Conclusion: Forced degradation analysis revealed the susceptibility of gimeracil to oxidative stress, leading to the generation of numerous degradation products. The developed LC-MS method proved effective in separating gimeracil from its degradation products, enabling comprehensive structural elucidation and identification.
References
[1]
World Health Organization (2020) Factsheets Details on Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer
[2]
Bray, F., Laversanne, M., Weiderpass, E. and Soerjomataram, I. (2021) The Ever‐Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide. Cancer, 127, 3029-3030. https://doi.org/10.1002/cncr.33587
[3]
Kobayakawa, M. and Kojima, Y. (2011) Tegafur/Gimeracil/Oteracil (S-1) Approved for the Treatment of Advanced Gastric Cancer in Adults When Given in Combination with Cisplatin: A Review Comparing It with Other Fluoropyrimidine-Based Therapies. OncoTargets and Therapy, 4, 193-201. https://doi.org/10.2147/ott.s19059
[4]
DeVita, V.T. and Chu, E. (2008) A History of Cancer Chemotherapy. Cancer Research, 68, 8643-8653. https://doi.org/10.1158/0008-5472.can-07-6611
[5]
Heidelberger, C., Chaudhuri, N.K., Danneberg, P., Mooren, D., Griesbach, L., Duschinsky, R., et al. (1957) Fluorinated Pyrimidines, a New Class of Tumour-Inhibitory Compounds. Nature, 179, 663-666. https://doi.org/10.1038/179663a0
[6]
Reni, M., Cereda, S. and Galli, L. (2007) PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) for Patients with Advanced Pancreatic Cancer: The Ghost Regimen. Cancer Letters, 256, 25-28. https://doi.org/10.1016/j.canlet.2007.04.009
Ikenaka, K. Shirasaka, T., Kitano, S. and Fujii, S. (1979) Effect of Uracil on Metabolism of 5-Fluorouracil in Vitro. GANN Japanese Journal of Cancer Research, 70, 353-359.
[9]
Sakata, K., Someya, M., Matsumoto, Y., Tauchi, H., Kai, M., Toyota, M., et al. (2011) Gimeracil, an Inhibitor of Dihydropyrimidine Dehydrogenase, Inhibits the Early Step in Homologous Recombination. Cancer Science, 102, 1712-1716. https://doi.org/10.1111/j.1349-7006.2011.02004.x
[10]
European Medicines Agency (EMA) (2024) Teysuno (Tegafur/Gimeracil/Oteracil) Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno
[11]
Yamada, H., Mizusawa, K., Igarashi, R., Tochio, H., Shirakawa, M., Tabata, Y., et al. (2012) Substrate/Product-Targeted NMR Monitoring of Pyrimidine Catabolism and Its Inhibition by a Clinical Drug. ACS Chemical Biology, 7, 535-542. https://doi.org/10.1021/cb2003972
[12]
Harada, K., Ferdous, T., Harada, T., Takenawa, T. and Ueyama, Y. (2017) Gimeracil Enhances the Antitumor Effect of Cisplatin in Oral Squamous Cell Carcinoma Cells in Vitro and in Vivo. Oncology Letters, 14, 3349-3356. https://doi.org/10.3892/ol.2017.6602
[13]
National Center for Biotechnology Information (2023) PubChem Compound Summary for CID 4604, Oxonic Acid. https://pubchem.ncbi.nlm.nih.gov/compound/Oxonic-Acid
[14]
Wen, L., You, C.W., Lu, X.Y. and Zhang, L. (2015) Phase II Trial of Concurrent Chemoradiotherapy with S-1 versus Weekly Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma. Molecular and Clinical Oncology, 3, 687-691. https://doi.org/10.3892/mco.2015.529
[15]
Chen, Y., Jiang, Y., Qu, J.J., Wang, Q.M., Bai, Y.X., Shi, J.H., et al. (2020) Pharmacokinetic and Bioequivalence Study of New S-1 Capsule in Chinese Cancer Patients. European Journal of Pharmaceutical Sciences, 151, Article 105384. https://doi.org/10.1016/j.ejps.2020.105384
[16]
Peer, C.J., McManus, T.J., Hurwitz, H.I. and Petros, W.P. (2012) Development and Utilization of a Combined LC-UV and LC-MS/MS Method for the Simultaneous Analysis of Tegafur and 5-Fluorouracil in Human Plasma to Support a Phase I Clinical Study of Oral Uft®/leucovorin. Journal of Chromatography B, 898, 32-37. https://doi.org/10.1016/j.jchromb.2012.04.010
[17]
Lee, H.W., Seong, S.J., Kang, W.Y., Ohk, B., Gwon, M., Kim, B.K., et al. (2019) Pharmacokinetic and Bioequivalence Study between Two Formulations of S-1 in Korean Gastric Cancer Patients. Drug Design, Development and Therapy, 13, 3127-3136. https://doi.org/10.2147/dddt.s219822
[18]
Sugiyama, E., Kaniwa, N., Kim, S., Hasegawa, R., Saito, Y., Ueno, H., et al. (2010) Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients. Clinical Pharmacokinetics, 49, 549-558. https://doi.org/10.2165/11532970-000000000-00000
[19]
Kochi, M., Fujii, M., Kanamori, N., Kaiga, T., Aizaki, K., Takahashi, T., et al. (2007) Effect of Gastrectomy on the Pharmacokinetics of S-1, an Oral Fluoropyrimidine, in Resectable Gastric Cancer Patients. Cancer Chemotherapy and Pharmacology, 60, 693-701. https://doi.org/10.1007/s00280-007-0415-x
[20]
Kim, T., Shin, S., Shin, J., Bulitta, J., Weon, K., Yoo, S., et al. (2017) Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling. Molecules, 22, Article 1488. https://doi.org/10.3390/molecules22091488
[21]
Liu, K., Zhong, D.F., Zou, H.Y. and Chen, X.Y. (2010) Determination of Tegafur, 5-Fluorouracil, Gimeracil and Oxonic Acid in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 52, 550-556. https://doi.org/10.1016/j.jpba.2010.01.026
[22]
Xu, H.Y., Liu, J.H., Qi, S.M., Zhou, L.Y., Su, M., Wang, Q.Q., et al. (2011) Method for Determining Related Substances of Tegafur, Gimeracil and Oteracil Potassium Capsules by Utilizing High Performance Liquid Chromatography. Patent No. CN102253152B.
[23]
Gu, Y.A., Lu, R., Si, D.Y. and Liu, C.X. (2009) Simultaneous Determination of Tegafur and Gimeracil in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. Analytical Sciences, 25, 1211-1215. https://doi.org/10.2116/analsci.25.1211
[24]
Liu, J., Xu, H., Qi, S., Zhou, L., Su, M., Wang, Q. and Chen, J.J. (2011) HPLC Method for De-Termining Related Substances in Tegafur Gimeracil Oteracil Potassium Capsule for Quality Control. Patent No. CN2011-10069859.
[25]
Matsushima, E., Yoshida, K., Kitamura, R. and Yoshida, K. (1997) Determination of S-1 (Combined Drug of Tegafur, 5-Chloro-2,4-Dihydroxypyridine and Potassium Oxonate and 5-Fluorouracil in Human Plasma and Urine Using High-Performance Liquid Chromatography and Gas Chromatography-Negative Ion Chemical Ionization Mass Spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications, 691, 95-104. https://doi.org/10.1016/s0378-4347(96)00429-x
[26]
Sun, L., Wang, Y.A., Zhai, G.X., Zhang, G.Z. and Sun, Q. (2006) Simultaneous RP-HPLC Determination of Tegafur, Gimestat and Potassium Oxonate in Compound Tegafur Capsules. Chinese Journal of Pharmaceutical Analysis., No. 8, 1115-1117.
[27]
Li, W.T., Lin, H., Song, N., Chen, G.Q., Li, X.B. and Zhao, H.K. (2019) Equilibrium Solubility Investigation and Thermodynamic Aspects of Biologically Active Gimeracil (Form P) Dissolved in Aqueous Co-Solvent Mixtures of Isopropanol, N,N-Dimethylformamide, Ethylene Glycol and Dimethylsulfoxide. The Journal of Chemical Thermodynamics, 133, 19-28. https://doi.org/10.1016/j.jct.2019.01.026
[28]
Liu, H.-Y., Ding, L., Yu, Y., Chu, Y. and Zhu, H. (2012) Comparison of Three Derivatization Reagents for the Simultaneous Determination of Highly Hydrophilic Pyrimidine Antitumor Agents in Human Plasma by LC-MS/MS. Journal of Chromatography B, 893-894, 49-56. https://doi.org/10.1016/j.jchromb.2012.02.033
[29]
Launay, M., Nasser, Y., Tholance, Y., Dellinger, S., Gonzalo, P. and Delavenne, X. (2020) Delaying Centrifugation and Freezing by Adding a Dihydropyrimidine Dehydrogenase Inhibitor Such as Gimeracil to Blood Sample Is Not a Valid Option to Simplify the Preanalytic Step for the Screening of Dihydropyrimidine Dehydrogenase Deficiency Using Uracilemia. Therapeutic Drug Monitoring, 42, 344-345. https://doi.org/10.1097/ftd.0000000000000716
[30]
Petřík, J., Zůza, D., Heřt, J., Řezanka, P., Krejčík, L., Hrubcová, K., et al. (2023) Azobisisobutyronitrile Loaded on Mesoporous Silica Particles: A New Stressor for Solid-State Oxidative Forced Degradation Studies. Journal of Pharmaceutical and Biomedical Analysis, 232, Article ID: 115417. https://doi.org/10.1016/j.jpba.2023.115417
[31]
Iyer, J., Karn, A., Brunsteiner, M., Ray, A., Davis, A., Saraf, I., et al. (2023) Screening Autoxidation Propensities of Drugs in the Solid-State Using PVP and in the Solution State Using N-Methyl Pyrrolidone. Pharmaceutics, 15, Article 848. https://doi.org/10.3390/pharmaceutics15030848
[32]
Iyer, J., Brunsteiner, M., Ray, A., Davis, A., Saraf, I. and Paudel, A. (2023) Theoretical and Experimental Investigation of Autoxidation Propensity of Selected Drugs in Solution State. Molecular Pharmaceutics, 20, 1768-1778. https://doi.org/10.1021/acs.molpharmaceut.2c00967
[33]
Iyer, J., Barbosa, M., Saraf, I., Pinto, J.F. and Paudel, A. (2023) Mechanoactivation as a Tool to Assess the Autoxidation Propensity of Amorphous Drugs. Molecular Pharmaceutics, 20, 1112-1128. https://doi.org/10.1021/acs.molpharmaceut.2c00841
[34]
Oyler, A.R., Segmuller, B.E., Sun, Y., Polshyna, A., Dunphy, R., Armstrong, B.L., et al. (2012) Forced Degradation Studies of Rapamycin: Identification of Autoxidation Products. Journal of Pharmaceutical and Biomedical Analysis, 59, 194-200. https://doi.org/10.1016/j.jpba.2011.10.017
[35]
Baertschi, S. and Alsante, K. (2005) Stress Testing. In: deSpautz, J.F., et al., Eds., Drugs and the Pharmaceutical Sciences, Informa Healthcare, 51-140.
[36]
Hovorka, S.W. and Schöneich, C. (2001) Oxidative Degradation of Pharmaceuticals: Theory, Mechanisms and Inhibition. Journal of Pharmaceutical Sciences, 90, 253-269.
[37]
Nelson, E.D., Harmon, P.A., Szymanik, R.C., Teresk, M.G., Li, L., Seburg, R.A., et al. (2006) Evaluation of Solution Oxygenation Requirements for Azonitrile-Based Oxidative Forced Degradation Studies of Pharmaceutical Compounds. Journal of Pharmaceutical Sciences, 95, 1527-1539. https://doi.org/10.1002/jps.20626
[38]
Reid, D.L., Calvitt, C.J., Zell, M.T., Miller, K.G. and Kingsmill, C.A. (2004) Early Prediction of Pharmaceutical Oxidation Pathways by Computational Chemistry and Forced Degradation. Pharmaceutical Research, 21, 1708-1717. https://doi.org/10.1023/b:pham.0000041469.96466.12
[39]
Nelson, E.D., Thompson, G.M., Yao, Y., Flanagan, H.M. and Harmon, P.A. (2009) Solvent Effects on the AIBN Forced Degradation of Cumene: Implications for Forced Degradation Practices. Journal of Pharmaceutical Sciences, 98, 959-969. https://doi.org/10.1002/jps.21489
[40]
Alsante, K.M., Martin, L. and Baertschi, S.W. (2003) A Stress Testing Benchmarking Study. Pharmaceutical Technology, 27, 60-72.
[41]
Reynolds, D.M., Facchine, K.L., Mullaney, J.F., Alsante, K.M., Hatajik, T.D. and Motto, M.G. (2002) Available Guidance and Best Practices for Conducting Forced Degradation Studies. Harmaceutical Technology, 26, 48-54.
[42]
Waterman, K.C., Adami, R.C., Alsante, K.M., Hong, J., Landis, M.S., Lombardo, F., et al. (2002) Stabilization of Pharmaceuticals to Oxidative Degradation. Pharmaceutical Development and Technology, 7, 1-32. https://doi.org/10.1081/pdt-120002237
[43]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2003) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline, Q1A (R2).
[44]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1996) Stability Testing: Photo-Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline, Q1B.
[45]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2006) Impurities in New Drug Substances. ICH Harmonised Tripartite Guideline, Q3A (R2).
[46]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1999) Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH Harmonised Tripartite Guideline, Q6A.
[47]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2005) Validation of Analytical Procedures: Text and Methodology. ICH Harmonised Tripartite Guideline, Q2 (R1).
[48]
Pal, A. and Sundararajan, R. (2024) Characterization of Forced Degradants of Tegafur, Gimeracil, and Oteracil Potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and Simultaneous Estimation of Triple Combination in Drug Substance and Finished Pharmaceutical Dosage Form. Archives of Razi Institute, 79, 287-302. https://Doi.Org/10.32592/ARI.2024.79.2.287.
[49]
Setsuro, F. (1991) 5-Fluorouracil Derivatives. US Patent No. 4983609A.
